Throwing the cells at the wall hoping they stick to something.
Looking back through the years how many exciting indications have there been based on small trials, and how many commercial products does MSB now have?
They need to pursue the indication they think the product works on and do the appropriate studies, focus on getting that commercialised and then branch out.
The shotgun approach isn't working.
Ann: FDA Grants Rare Pediatric Disease Designation for Revascor, page-152
-
- There are more pages in this discussion • 229 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
-0.025(2.17%) |
Mkt cap ! $1.284B | |||
| Open | High | Low | Value | Volume |
| $1.15 | $1.16 | $1.11 | $7.363M | 6.488M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 94863 | $1.13 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.13 | 5000 | 2 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |